NEW YORK, Sept 6 Amersham Pharmacia Biotech said on Wednesday it had invested $10 million in InforMax and also announced a strategic collaboration with the bioinformatics company.
The deal represents the largest collaboration for InforMax of Rockville, Md., to date.
Under the terms of the deal Amersham, the Piscataway, N.J.-based life sciences division of Nycomed Amersham (NYSE: NYE; LSE: NAM), and InforMax will work together to expand the capability of InforMax’s GenoMax bioinformatics product.
The companies plan on creating a data analysis system that will allow pharmaceutical companies to merge and analyze genomics, pharmacogentics, proteomics and drug screening data.
The companies will share the proceeds from marketing and distributing the new product.
“Our goal is to expand our bioinformatics business by integrating our diverse high throughput platforms into a higher value proposition for our pharmaceutical industry customers,” Andrew Whiteley, vice president of bioinformatics at Amersham Pharmacia Biotech, said in a statement.
Amersham could not immediately be reached for comment.
A spokesman for InforMax declined to comment on the deal, saying the company is in a quiet period in the run up to its planned initial public offering on the Nasdaq.